These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 16298418)
1. Changes in acetylator phenotype over the lifespan in the Wistar rat. Lares-Asseff I; Camacho GA; Guillé AJ; Toledo AR; Trujillo F; Reyes RE; Juárez HM; Pérez G Mech Ageing Dev; 2006 Jan; 127(1):73-8. PubMed ID: 16298418 [TBL] [Abstract][Full Text] [Related]
2. Acetylator phenotyping in patients with malignant lymphomas, using caffeine as the metabolic probe. William BM; Abdel-tawab AM; Hassan EA; Mohamed OF Pol J Pharmacol; 2004; 56(4):445-9. PubMed ID: 15520499 [TBL] [Abstract][Full Text] [Related]
3. Sulphamethoxazole acetylation in fast and slow acetylators. Bozkurt A; Basci NE; Isimer A; Tuncer M; Erdal R; Kayaalp SO Int J Clin Pharmacol Ther Toxicol; 1990 Apr; 28(4):164-6. PubMed ID: 2338369 [TBL] [Abstract][Full Text] [Related]
4. Incidence of isoniazid acetylation phenotypes in North Indians. Gupta RC; Nair CR; Jindal SK; Malik SK Int J Clin Pharmacol Ther Toxicol; 1984 May; 22(5):259-64. PubMed ID: 6746149 [TBL] [Abstract][Full Text] [Related]
5. N-acetylation of drugs. Pharmacogenetic studies in rabbits selected for their acetylator characteristics. Weber WW; Miceli JN; Hearse DJ; Drummond GS Drug Metab Dispos; 1976; 4(1):94-101. PubMed ID: 3408 [TBL] [Abstract][Full Text] [Related]
6. Phase I study of amonafide dosing based on acetylator phenotype. Ratain MJ; Mick R; Berezin F; Janisch L; Schilsky RL; Vogelzang NJ; Lane LB Cancer Res; 1993 May; 53(10 Suppl):2304-8. PubMed ID: 8485716 [TBL] [Abstract][Full Text] [Related]
7. Isoniazid acetylation metabolic ratio during maturation in children. Pariente-Khayat A; Rey E; Gendrel D; Vauzelle-Kervroëdan F; Crémier O; d'Athis P; Badoual J; Olive G; Pons G Clin Pharmacol Ther; 1997 Oct; 62(4):377-83. PubMed ID: 9357388 [TBL] [Abstract][Full Text] [Related]
8. [Acetylation of sulfadimezine and ethazole in rats]. Krylov IuF; Lil'in ET; Vaniukov MM; Monastyrskaia AR; Isaeva IV Farmakol Toksikol; 1982; 45(4):85-8. PubMed ID: 7128797 [TBL] [Abstract][Full Text] [Related]
9. Bioavailability factors of isoniazid in fast and slow acetylators, healthy volunteers. Augustynowicz-Kopeć E; Zwolska Z Acta Pol Pharm; 2002; 59(6):452-7. PubMed ID: 12669770 [TBL] [Abstract][Full Text] [Related]
10. Sulfadimidine and isoniazid loading in man and laboratory rats. Pharmacokinetic and pharmacogenetic results on drug acetylation. Dubbels R; Kattner E; Sell-Maurer D; Schloot W Arzneimittelforschung; 1980; 30(9):1574-9. PubMed ID: 7193028 [TBL] [Abstract][Full Text] [Related]
11. Comparison between serum and urinary sulphadimidine acetylation as predictors of isoniazid acetylator status in patients with pulmonary tuberculosis. Singh SP; Pande JN; Khilnani GC; Kailash S Indian J Chest Dis Allied Sci; 1996; 38(1):5-11. PubMed ID: 16892742 [TBL] [Abstract][Full Text] [Related]
12. Acetylation status is associated with serological changes but not clinically significant disease in patients receiving procainamide. Mongey AB; Sim E; Risch A; Hess E J Rheumatol; 1999 Aug; 26(8):1721-6. PubMed ID: 10451068 [TBL] [Abstract][Full Text] [Related]
13. Acetylator phenotype in Iraqi patients with atopic dermatitis. Najim RA; Al-Waiz MM; Al-Razzuqi RA Dermatol Online J; 2006 Dec; 12(7):1. PubMed ID: 17459287 [TBL] [Abstract][Full Text] [Related]
14. Acetylator phenotype in Iraqi patients with systemic lupus erythematosus. Najim RA; Farid YY; Samad TA; Shihab SA East Mediterr Health J; 2005; 11(5-6):1003-8. PubMed ID: 16761671 [TBL] [Abstract][Full Text] [Related]
15. N-acetylation in healthy and diseased children. Hadasová E; Brysová V; Kadlcáková E Eur J Clin Pharmacol; 1990; 39(1):43-7. PubMed ID: 2276387 [TBL] [Abstract][Full Text] [Related]